knowledge -WSS

knowledge

author：knowledge 2025-10-02 13:01:34 - browse：257

Most everything is looking up for Orexo, the company reported on its second quarter earnings call on Tuesday. That is, everything but its digital therapies pipeline.

The Swedish pharmaceutical company, which makes almost all of its money from U.S. sales of its drug for opioid dependence, notched a number of important victories in the quarter: It successfully defended its patents in a case against Sun Pharmaceuticals, it resolved a packaging issue that was holding up the approval of its long-acting rescue medication, and it grew revenues for Zubsolv, its most important product. The company trimmed its losses to 12.6 million SEK, or $1.2 million, and executives reported that with fewer one-time expenses on the horizon, profitability was “in sight.”

“We are at an exciting turning point for the company and I hope our self confidence and optimism is something that you can share,” CEO Nikolaj Sørensen said on the company’s earnings call while cautioning that “there’s a lot more work to be done.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Problems with a popular proposal to regulate AI in health care

focus

WSS

Unique patient identifier: Experts argue the benefits, pitfalls

PBMs drew scrutiny in House hearing — and so did pharma

Assistant physicians can help address the primary care shortage

PBMs drew scrutiny in House hearing — and so did pharma

Midwives could help bridge maternal health disparities in the U.S.

Problems with a popular proposal to regulate AI in health care

entertainment

knowledge

explore

What does generative AI mean for health care? We asked experts

Problems with a popular proposal to regulate AI in health care

Dobbs anniversary: the lost opportunity of abortion as health care

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medicare details structure of new drug price negotiation program

'A game

Psychedelics group wrestles with new pharma identity

Free Covid tests will again be offered to all U.S. households

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare to pay more for cardiac rehab in hospital outpatient clinics

leisure time

The Biogen Aduhelm mess could happen again

Patients, doctors press FTC to beef up hospital merger scrutiny

Why the drug industry's warnings on the IRA's impact fall short

Patients, doctors press FTC to beef up hospital merger scrutiny

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Readout Newsletter: Amgen, Regeneron, BGI Group and more

leisure time

entertainment

focus

leisure time